Axogen vs Establishment Labs
AXGN and ESTA side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AXGN and ESTA compare
Axogen is the larger company, worth 1.6 times as much as Establishment Labs ($3.3B against $2.1B).
Establishment Labs grew revenue faster over the last twelve months (38.3% versus 24.3% for Axogen).
Axogen keeps more of each dollar of sales as profit, with a net margin of −12.0% compared with −14.6% at Establishment Labs.
Axogen scores higher on the StockData Score (11 against 6 for Establishment Labs), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AXGN | ESTA |
|---|---|---|
| Size and price | ||
| Market cap | $3.3B | $2.1B |
| Share price | $55.37 | $69.51 |
| Change, 1 year | 135% | 8.6% |
| Change, 5 years | 477% | 4.7% |
| Beta (5Y) | 1.32 | 0.67 |
| Employees | 622 | 1,004 |
| StockData Score | ||
| Total score | 11 (better) | 6 |
| Valuation score | 0 | 0 |
| Growth score | 3 | 3 |
| Performance score | 3 (better) | 2 |
| Health score | 5 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 12.4× | 7.8× (better) |
| P/B | 6.7× (better) | 133× |
| P/FCF | 150× | – |
| FCF yield | 0.67% (better) | −1.0% |
| Fair value | $22.90 | – |
| Margin of safety | −142% | – |
| Growth | ||
| Revenue growth (TTM) | 24.3% | 38.3% (better) |
| Revenue growth, 5Y average | 14.9% | 20.0% (better) |
| Profitability | ||
| Gross margin | 74.2% (better) | 70.2% |
| Operating margin | −5.2% (better) | −6.6% |
| Net margin | −12.0% (better) | −14.6% |
| FCF margin | 8.3% (better) | −8.2% |
| Return on equity | −10.3% (better) | −241% |
| Return on invested capital | −7.9% | −6.7% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 17.17 (better) |
| Interest coverage | −5.7× | −0.6× (better) |
| Current ratio | 12.02 (better) | 3.57 |
| Altman Z-score | 37.04 (better) | 2.74 |
| Piotroski F-score | 5 (better) | 3 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 90.4% | 95.8% |
| Held by insiders | 7.6% | 9.6% |
| Insider net buying, 12 months | −$17.1M (better) | −$35.5M |
| Short interest, % of float | 12.7% | 14.6% |
Go deeper
- AXGN stock overview
- AXGN income statement
- AXGN valuation and score
- ESTA stock overview
- ESTA income statement
- ESTA valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.